Advertisement
Advertise here Publish your press releases here Sponsor BioPortfolio
Follow us on Twitter Sign up for daily news and research emails Contributors wanted

Bluebird’s Gene Therapy Quickly Halts Blood Disease in Small Study

10:08 EDT 14 Jun 2014 | Xconomy

As a gene therapy company, Bluebird Bio was a surprising IPO star in 2013. After all, it’s working in a field that was kicked to the curb in the previous decade. What’s more, it made its IPO pitch on the back of the slimmest amount of data. But d...

Original Article: Bluebird’s Gene Therapy Quickly Halts Blood Disease in Small Study

NEXT ARTICLE

More From BioPortfolio on "Bluebird’s Gene Therapy Quickly Halts Blood Disease in Small Study"

Search BioPortfolio: